June 17, 2024 03:31 PM EDT
Pharma
FDA+

FDA ap­proves en­dome­tri­al can­cer in­di­ca­tions for Keytru­da, Imfinzi

Nicole DeFeudis

Editor

The FDA has grant­ed two new en­dome­tri­al can­cer in­di­ca­tions to ri­val im­munother­a­pies: Mer­ck’s Keytru­da and As­traZeneca’s Imfinzi.

On Mon­day, reg­u­la­tors

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

FDA ap­proves Dupix­ent in COPD, open­ing ‘next chap­ter’ for Sanofi and Re­gen­eron’s best­seller

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times